Precigen, Inc.
PGEN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001356090
In the last 90 days, Precigen, Inc. insiders filed 1 open-market purchase and 6 sales; 210 institutions reported holding it in 13F filings for Q2 2026, worth $799.4M in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in Precigen, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 206
- +31 vs. Q4 2025
- Shares held
- 133.6M
- +8.38M (+6.7%) vs. Q4 2025
- Total value
- $516.7M
- −$6.87M (−1.3%) vs. Q4 2025
- New holders
- 48
- 67 more added
- Sold out
- 17
- 47 more reduced
4 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PGEN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 210 | $799.4M |
| Q1 2026 | 206 | $516.7M |
| Q4 2025 | 179 | $568.5M |
| Q3 2025 | 167 | $366.2M |
| Q2 2025 | 147 | $116.6M |
| Q1 2025 | 138 | $119.3M |
| Q4 2024 | 133 | $84.8M |
| Q3 2024 | 127 | $71.7M |
| Q2 2024 | 130 | $95.9M |
| Q1 2024 | 129 | $89.4M |
| Q4 2023 | 137 | $83.9M |
| Q3 2023 | 138 | $86.0M |
| Q2 2023 | 138 | $66.0M |
| Q1 2023 | 157 | $65.1M |
| Q4 2022 | 161 | $64.3M |
| Q3 2022 | 165 | $265.0M |
| Q2 2022 | 169 | $182.2M |
| Q1 2022 | 173 | $302.8M |
| Q4 2021 | 168 | $529.9M |
| Q3 2021 | 172 | $690.3M |
| Q2 2021 | 150 | $926.2M |
| Q1 2021 | 166 | $978.6M |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Precigen, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Point72 Asset Management, L.P. | 6,644,361 | $25.7M | 0.04% | −7,079,780−51.6% | Reduced |
| Diametric Capital, LP | 6,801,788 | $26.3M | 6.90% | +2,954,764+76.8% | Added |
| Vanguard Capital Management LLC | 7,148,996 | $27.7M | 0.00% | +7,148,996 | New |
| State Street Corp | 10,890,124 | $42.1M | 0.00% | +65,264+0.6% | Added |
| BlackRock, Inc. | 15,223,191 | $58.9M | 0.00% | +128,832+0.9% | Added |
| Patient Capital Management, LLC | 17,817,387 | $69.0M | 2.57% | −856,079−4.6% | Reduced |
| SymBiosis Capital Partners, LLC | 0 | $0 | 0.00% | −3,000,000−100.0% | Sold out |
| Parkman Healthcare Partners LLC | 0 | $0 | 0.00% | −1,002,826−100.0% | Sold out |
| EAM Investors, LLC | 0 | $0 | 0.00% | −405,001−100.0% | Sold out |
| Impala Asset Management LLC | 0 | $0 | 0.00% | −165,000−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −73,100−100.0% | Sold out |
| Atom Investors LP | 0 | $0 | 0.00% | −61,825−100.0% | Sold out |
| VARCOV Co. | 0 | $0 | 0.00% | −53,522−100.0% | Sold out |
| Polen Capital Management LLC | 0 | $0 | 0.00% | −42,095−100.0% | Sold out |
| Susquehanna Portfolio Strategies, LLC | 0 | $0 | 0.00% | −30,482−100.0% | Sold out |
| Brevan Howard Capital Management LP | 0 | $0 | 0.00% | −26,267−100.0% | Sold out |
| Daiwa Securities Group Inc. | 0 | $0 | 0.00% | −20,265−100.0% | Sold out |
| NBC Securities, Inc. | 0 | $0 | 0.00% | −9,015−100.0% | Sold out |
| Amalgamated Bank | 0 | $0 | 0.00% | −5,664−100.0% | Sold out |
| Parallel Advisors, LLC | 0 | $0 | 0.00% | −522−100.0% | Sold out |
| Vermillion & White Wealth Management Group, LLC | 0 | $0 | 0.00% | −450−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −46−100.0% | Sold out |
| The PNC Financial Services Group, Inc. | 0 | $0 | 0.00% | −19−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |
| CIBC Private Wealth Group, LLC | – | – | – | – | Not filed |
| CIBC World Markets Corp | – | – | – | – | Not filed |
| Comerica Bank | – | – | – | – | Not filed |